Allogeneic hematopoietic cell transplantation (allo-HCT) is an essential therapeutic modality
for patients with hematological malignancies and other blood disorders. Unfortunately, acute …

Over the past 5 years, many novel approaches to early diagnosis, prevention, and treatment
of acute graft-versus-host disease (aGVHD) have been translated from the bench to the …

Background Responses to conventional donor lymphocyte infusion for postallogeneic
hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell …

BACKGROUND. Graft-versus-host disease (GVHD) is a major cause of morbidity and
mortality following allogeneic hematopoietic stem cell transplantation (HCT). In mice, naive T …

PURPOSE Graft-versus-host disease (GVHD) causes morbidity and mortality following
allogeneic hematopoietic cell transplantation. Naive T cells (TN) cause severe GVHD in …

The use of allogeneic hematopoietic cell transplantation (HCT) has increased as new
techniques have been developed for transplantation in patients who previously would not …

The most common cause of post-transplant mortality in patients with hematological
malignancy is relapse, followed by GvHD, infections, organ toxicity and second malignancy …

Graft-versus-host disease (GVHD) is a frequent major complication of allogeneic
hematopoietic cell transplantation (HCT). Approaches that selectively deplete T cells that …

Hematopoietic stem cell transplantation from a haploidentical donor is increasingly used
and has become a standard donor option for patients lacking an appropriately matched …

In allogeneic hemopoietic stem cell transplantation, mature donor αβ T cells in the allograft
promote T cell reconstitution in the recipient and mediate the graft-vs-leukemia (GVL) effect …